By Juhi Kunde, MA, February 13, 2017

Patrick Forde, MD, has a lot of experience running clinical trials. At any given time, he is running five to ten active clinical trials for patients with lung cancer at Johns Hopkins University. These trials span the full spectrum from early-stage to metastatic lung cancer. The majority of the trials he runs involve the use of immunotherapy drugs—drugs that leverage our natural immune system to combat disease.

By Kenneth Lourie, February 9, 2017

Kenneth Lourie

In spite of mostly-successfully not being preoccupied with my condition/circumstances/disease, when a lung cancer survivor dies, even one with whom I've had minimal contact; one whom I could barely call an acquaintance, the link in the chain that makes all of us lung cancer patients/survivors stronger is most definitely effected.

By Juhi Kunde, MA, January 17, 2017

Viswam Nair, MDEach year Viswam Nair, MD, manages treatment plans for hundreds of patients at Stanford University. A pulmonologist with formal training in epidemiology, Dr. Nair stays current on the latest scientific breakthroughs to offer his patients the best possible outcomes.

By Upal Basu Roy, MPH, PhD, December 19, 2016

Audio of interview with Dr Christine LovlyTargeted therapies continue to be an important treatment option for those patients whose tumors test positive for an actionable mutation for which a drug exists.

Share Your Story

Submit your story, blog idea, or lung cancer-specific article on the many issues people affected by lung cancer face

LUNGevity Spotlight

Nominate someone living with lung cancer or a caregiver, volunteer, or fundraiser who is making a positive impact in the LUNGevity community.

Ask Nutrition Questions

Your questions may be answered in an upcoming Savor Health blog post!